Abstract Number: 750 • 2017 ACR/ARHP Annual Meeting
Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers
Background/Purpose: Assessing the effect of Diltiazem gel on healing process of scleroderma digital ulcers and comparing its effect with Nitroglycerin ointment and placebo. Methods: Ninety…Abstract Number: 803 • 2016 ACR/ARHP Annual Meeting
Multi-Organ RNA-Sequencing of Systemic Sclerosis (SSc) Patients Shows Reproducible Gene Expression Profiles Across Organ Systems
Background/Purpose: While a hallmark of systemic sclerosis (SSc) is skin fibrosis, internal organ involvement is the primary cause of mortality. Pulmonary Arterial Hypertension (PAH), Interstitial…Abstract Number: 1850 • 2016 ACR/ARHP Annual Meeting
Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Background/Purpose: The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. Traditionally, daily subcutaneous injections of BLM for 4-6…Abstract Number: 2896 • 2016 ACR/ARHP Annual Meeting
Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers
Background/Purpose: Vascular complications of systemic sclerosis (SSc, scleroderma) can result in ulcers in the distal extremities, which limit function and are often refractory to conventional…Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…Abstract Number: 1080 • 2015 ACR/ARHP Annual Meeting
Modified Rodnan Skin Score Thresholds for the Optimization of Cohort Enrichment in Clinical Trials in Skin Fibrosis in Patients with Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: The modified Rodnan skin score (mRSS) is the major outcome measure for skin fibrosis in clinical trials (CT) in diffuse cutaneous scleroderma (dcSSc). Traditionally,…Abstract Number: 1887 • 2015 ACR/ARHP Annual Meeting
Deficiency in Micronutrients Is a Frequent Burden in Patients with Systemic Sclerosis
Background/Purpose: Micronutrients are essential dietary factors involved in many metabolic processes, including oxidative stress, collagen synthesis and wound healing, which are key aspects of the…Abstract Number: 1895 • 2015 ACR/ARHP Annual Meeting
Correlation of Scleroderma Interstitial Lung Disease with Gastroesophageal Reflux
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease involving the skin and visceral organs, most commonly the gastrointestinal tract and lungs. Interstitial lung disease…Abstract Number: 1912 • 2015 ACR/ARHP Annual Meeting
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Immune Abnormalities in Animal Models of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and fibrosis of the skin and various internal organs. Glycyrrhizin, a triterpenoid saponin…Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting
Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…Abstract Number: 2961 • 2015 ACR/ARHP Annual Meeting
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Background/Purpose: Arthropathy and tendinopathy in Systemic Sclerosis (SSc) contribute to disability and are associated with disease progression. Clinical trials in SSc sometimes include the tender…Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…Abstract Number: 746 • 2014 ACR/ARHP Annual Meeting
Elevated Pentraxin 3 in Patients with Systemic Sclerosis: Associations with Vascular Manifestations and Defective Vasculogenesis
Background/Purpose: Pentraxin 3 (PTX3) is a multi-functional pattern recognition protein involved in inflammation, extracellular matrix deposition, and suppression of neovascularization mediated by fibroblast growth factor-2…Abstract Number: 734 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose Lower socioeconomic status (SES) and male gender have been associated with worse survival in idiopathic pulmonary arterial hypertension (PAH). Pulmonary Hypertension Assessment and Recognition…